MARKET

RIGL

RIGL

Rigel Pharmaceuticals Inc
NASDAQ
38.53
+1.54
+4.16%
Opening 10:19 06/26 EDT
OPEN
37.17
PREV CLOSE
36.99
HIGH
38.54
LOW
37.00
VOLUME
27.99K
TURNOVER
--
52 WEEK HIGH
52.24
52 WEEK LOW
18.14
MARKET CAP
712.89M
P/E (TTM)
2.090
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RIGL last week (0615-0619)?
Weekly Report · 4d ago
A Look At The Transformation Around Rigel Pharmaceuticals
Seeking Alpha · 6d ago
As U.S. profit margins near record highs, these small-cap stocks lead on profitability
Seeking Alpha · 06/18 11:43
Rigel Expands Oncology Portfolio with VEPPANU Global Rights
TipRanks · 06/17 21:24
Rigel Pharmaceuticals pays $70 million upfront for global rights to Arvinas-Pfizer breast cancer drug VEPPANU
PUBT · 06/17 20:06
These small-cap healthcare stocks pair revenue growth with attractive valuations
Seeking Alpha · 06/17 11:02
Rigel to roll out Veppanu in August; Arvinas, Pfizer snag $70M upfront on cleared deal
Seeking Alpha · 06/17 07:17
Rigel Pharmaceuticals publishes corporate presentation outlining commercial growth strategy and pipeline priorities
PUBT · 06/16 20:25
More
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.

Webull offers Rigel Pharmaceuticals Inc stock information, including NASDAQ: RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RIGL stock methods without spending real money on the virtual paper trading platform.